Cargando…

From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montemagno, Christopher, Cassim, Shamir, Pouyssegur, Jacques, Broisat, Alexis, Pagès, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312874/ https://www.ncbi.nlm.nih.gov/pubmed/32517181 http://dx.doi.org/10.3390/ijms21114067

Ejemplares similares

(99m)Tc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
por: Montemagno, Christopher, et al.
Publicado: (2019)

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
por: Montemagno, Christopher, et al.
Publicado: (2021)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma
por: Aksoy, Asude, et al.
Publicado: (2023)

Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response
por: Cassim, Shamir, et al.
Publicado: (2019)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Metabolic Rewiring toward Oxidative Phosphorylation Disrupts Intrinsic Resistance to Ferroptosis of the Colon Adenocarcinoma Cells
por: Gotorbe, Célia, et al.
Publicado: (2022)

Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer
por: Cassim, Shamir, et al.
Publicado: (2020)

Together we stand, apart we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis
por: Vucetic, Milica, et al.
Publicado: (2020)

Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential
por: Cannon, Andrew, et al.
Publicado: (2018)

Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
por: Jain, Aditi, et al.
Publicado: (2021)

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma: Current and Emerging Therapeutic Uses of Focused Ultrasound
por: Lafond, Maxime, et al.
Publicado: (2022)

Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
por: Bijlsma, Maarten F., et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
por: Adamska, Aleksandra, et al.
Publicado: (2017)

Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
por: Sally, Áine, et al.
Publicado: (2022)

Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer
por: White, Michael, et al.
Publicado: (2018)

A Cystine-Cysteine Intercellular Shuttle Prevents Ferroptosis in xCT(KO) Pancreatic Ductal Adenocarcinoma Cells
por: Meira, Willian, et al.
Publicado: (2021)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
por: Tong, Yexin, et al.
Publicado: (2022)

Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
por: Ayres Pereira, Marina, et al.
Publicado: (2019)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
por: Fan, Jia-qiao, et al.
Publicado: (2020)

Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma
por: Shen, Jiayu, et al.
Publicado: (2020)

Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
por: Thakur, Gitika, et al.
Publicado: (2021)

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
por: Liu, Jinlu, et al.
Publicado: (2023)

MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma
por: Ding, Feng, et al.
Publicado: (2017)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma
por: Nakaoka, Kazunori, et al.
Publicado: (2023)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Ral GTPase–activating protein regulates the malignancy of pancreatic ductal adenocarcinoma
por: Yoshimachi, Shingo, et al.
Publicado: (2021)

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics
por: Ocal, Ozhan, et al.
Publicado: (2015)

Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?
por: Crippa, Stefano, et al.
Publicado: (2017)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
por: Rai, Vikrant, et al.
Publicado: (2020)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
por: Prinz, Christian, et al.
Publicado: (2022)

Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
por: Creeden, Justin F., et al.
Publicado: (2020)

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies
por: Benloucif, Abdennour, et al.
Publicado: (2023)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_16qmt5k7q6dev93fr58tqka3j8